# Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia

> **NCT01670812** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** FFP+HDMP+Rituximab

## Key facts

- **NCT ID:** NCT01670812
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2013-06
- **Final completion:** 2014-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2012-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01670812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01670812, "Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01670812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*